NMRA · Neumora Therapeutics, Inc.
$1.60
-0.13 (-7.51%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$300.63M
Shares
187.90M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-02-17 | Milligan Michael Lee | Officer | 1,436 | 2026-02-17 | Merrill Lynch |
| 2026-02-17 | BERNS PAUL L | Officer | 9,819 | 2026-02-17 | Merrill Lynch |
| 2026-02-17 | Pinto Joshua | Officer | 5,967 | 2026-02-17 | Merrill Lynch |
| 2026-02-17 | Aurora Daljit Singh | Officer | 6,165 | 2026-02-17 | Merrill Lynch |
| 2025-11-12 | Aurora Family Trust | Director, Officer | 114,703 | 2025-11-11 | Merrill Lynch |
| 2025-03-12 | Henry Gosebruch | Officer, Director | 15,000 | 2025-03-12 | J.P. Morgan Securities LLC |
| 2025-02-18 | Pinto Joshua | Officer | 8,048 | 2025-02-18 | Merrill Lynch |
| 2025-02-18 | Gosebruch Henry O | Officer, Director | 6,857 | 2025-02-18 | Merrill Lynch |
| 2025-02-18 | Aurora Daljit Singh | Officer | 8,565 | 2025-02-18 | Merrill Lynch |
| 2025-02-18 | Suh Carol Y. | Officer | 9,540 | 2025-02-18 | Merrill Lynch |
| 2025-02-18 | BERNS PAUL L | Officer | 13,871 | 2025-02-18 | Merrill Lynch |
| 2025-02-18 | Lenz Robert A. | Officer | 5,614 | 2025-02-18 | Merrill Lynch |
| 2025-02-18 | Milligan Michael Lee | Officer | 1,978 | 2025-02-18 | Merrill Lynch |
| 2024-10-18 | Fust Matthew K | Director | 14,049 | 2024-10-18 | Merrill Lynch |
| 2024-10-17 | Fust Matthew K | Director | 7,739 | 2024-10-17 | Merrill Lynch |
| 2024-10-10 | Lenz Robert A. | Officer | 8,260 | 2024-10-10 | Merrill Lynch |
| 2024-10-09 | Lenz Robert A. | Officer | 5,563 | 2024-10-09 | Merrill Lynch |
| 2024-09-18 | Lenz Robert A. | Officer | 10,676 | 2024-09-18 | Merrill Lynch |
| 2024-09-17 | Lenz Robert A. | Officer | 30,788 | 2024-09-17 | Merrill Lynch |
| 2024-09-12 | Lenz Robert A. | Officer | 32,948 | 2024-09-12 | Merrill Lynch |
| 2024-08-22 | Pinto Joshua | Officer | 100,000 | 2024-08-22 | Merrill Lynch |
Showing 1–21 of 21 filings
Key facts
CIK
1885522
CUSIP
640979100
13F (30d)
114 filings
112 filers
Visit website
Investor relations